PRODISC TM-C TOTAL DISC REPLACEMENT
Centinel Spine, LLC · Decision date Dec 17, 2007
What did the FDA approve?
FDA approved the ProDisc-C Total Disc Replacement on December 17, 2007, for skeletally mature patients requiring reconstruction of the disc from C3-C7 after single-level discectomy for intractable symptomatic cervical disc disease. The device is implanted through an open anterior approach. Patients must have failed at least six weeks of non-operative treatment before implantation.
Symptomatic cervical disc disease is defined in the approval as neck or arm (radicular) pain and/or a functional/neurological deficit with at least one imaging-confirmed condition: herniated nucleus pulposus, spondylosis defined by osteophytes, and/or loss of disc height. The statement reports the approved indication and conditions; it does not independently establish safety or clinical effectiveness.
FDA approval order statement
APPROVAL FOR THE PRODISC-C TOTAL DISC REPLACEMENT. THE DEVICE IS INDICATED FOR SKELETALLY MATURE PATIENTS FOR RECONSTRUCTION OF THE DISC FROM C3-C7 FOLLOWING SINGLE-LEVEL DISCECTOMY FOR INTRACTABLE SYMPTOMATIC CERVICAL DISC DISEASE (SCDD). SYMPTOMATIC CERVICAL DISC DISEASE IS DEFINED AS NECK OR ARM (RADICULAR) PAIN AND/OR A FUNCTIONAL/NEUROLOGICAL DEFICIT WITH AT LEAST ONE OF THE FOLLOWING CONDITIONS CONFIRMED BY IMAGING (CT, MRI, OR X-RAYS): HERNIATED NUCLEUS PULPOSUS, SPONDYLOSIS (DEFINED BY THE PRESENCE OF OSTEOPHYTES), AND/OR LOSS OF DISC HEIGHT. THE PRODISC-C TOTAL DISC REPLACEMENT IS IMPLANTED VIA AN OPEN ANTERIOR APPROACH. PATIENTS RECEIVING THE PRODISC-C TOTAL DISC REPLACEMENT SHOULD HAVE FAILED AT LEAST SIX WEEKS OF NON-OPERATIVE TREATMENT PRIOR TO IMPLANTATION OF THE PRODISC-C TOTAL DISC REPLACEMENT.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Orthopedic
- Decision date
- Dec 17, 2007
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P070001
- Regulatory pathway
- Premarket approval application
- Applicant
- Centinel Spine, LLC
- Product code
- MJO
- Decision code
- APPR
- Decision date
- Dec 17, 2007
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, intervertebral disc.
- Applicant
- Centinel Spine, LLC
- Product code
- MJO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P070001 received
Application receipt date recorded by FDA.
P070001 · FDA decision
APPR
P070001/S031 · Related supplement
prodisc C Nova
Timeline entries are records held by MedtechLedger for P070001. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P070001
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
prodisc C NovaP070001/S031 | Centinel Spine, LLC | PMA supplement | Sep 9, 2026 | FDA |
Explore the linked device profile
Other records with product code MJO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BAGUERAC Cervical Disc ProsthesisP250042/S002 | Spineart USA, Inc. | PMA supplement | Sep 22, 2026 | FDA |
Synergy DiscP250028/S003 | Synergy Spine Solutions, Inc. | PMA supplement | Sep 17, 2026 | FDA |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
| Spineart USA, Inc. | PMA approval | Aug 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Centinel Spine, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 900 Airport Rd., Suite 3b, West Chester, PA, 19380
Sources and methodology
- Original FDA record: P070001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



